Learn about Erectile Dysfunction and Sildenafil Citrate Online

Have you ever wondered how sildenafil acts within your body to help you solve your problems with erectile dysfunction?  Thanks to the instant availability of the Internet and computer devices, you will now be able to learn about ED and sildenafil citrate online right at your fingertips.

If you are curious as to how PDE5 inhibitors such as sildenafil work inside your body, then you can browse on search engines by simply typing in the search box the words sildenafil citrate online.  When you read about the mechanics of the action of sildenafil citrate online, you will learn that it helps protect the enzyme cGMP (short for cyclic guanosine monophosphate) from being degraded by the cGMP-specific PDE5 (short for phosphodiesterase type 5 enzyme) which are evidently located in the penile corpus cavernosum of men.  The free radical NO (short for nitric oxide) found in the penile corpus cavernosum adheres itself to what are called the guanylate cyclase receptors, which then results to the occurrence of elevated amounts of cGMP, thereby leading to the vasodilation or relaxation of the smooth muscles of the inner lining cushions of the helicine arteries (tendril-like arteries of the penis importantly involved in the process of its erection).  Once the smooth muscles relax, it will result to vasodilation and therefore there will be an increased supply of blood flowing into the penile spongy tissue, and the end result would be a successful penile erection.

Additionally, what you would also learn about sildenafil citrate online is that its special molecular makeup is somewhat similar to cGMP (located in the penile corpus cavernosum as well) and functions as an aggressive binding element of PDE5 in the penile corpus cavernosum, which results to more concentrations of cGMP and even better occurrences of erections. Avery important information that men will learn through reading about sildenafil citrate online is that sildenafil will be rendered useless without the introduction of one or more sexual stimuli, since only a sexual stimulus will be the only factor that can initiate the activation of the nitric oxide and cGMP inside a man’s body. Read more…

New fibrage-statin combos work their way through the system


The FDA is looking for more data to support a new US drug application for a product called Certriad which combines two cholesterol meds -- Abbott's TriLipix and AstraZeneca's Crestor.

TriLipix is a class of drugs called fibrages that boost "good" cholesterol and reduce triglycerides, a fat found in the blood stream, and "bad" cholesterol. Crestor is a statin that raises "good" HDL cholesterol while reducing "bad" HDL cholesterol.

The new product is intended to treat dyslipikemia, which results from elevated cholesterol and triglycerides. More than 100 million Americans suffer from the disorder says The American Heart Association.

The companies will continue to work with the FDA.

Studies on the effectiveness of statins in the prevention of cardiovascular disease are ongoing. One of many was reported in Journal Watch Cardiology last August by Dr Harlan Krumholz It results came from of an analysis of 10 trials with over 70,000 subjects over an average of 4 years, mean age 63, mean baseline LDL level 140, 2/3rds were male., ¼ of those had diabetes. Mortality was 5.7% in the control groups and 5.1% in the statin group. Go to http://bit.ly/bqbdnc for more.

The study concluded that statins can reduce the risk of cardiovascular events in those without cardiovascular disease.

1 comments:

said...

IF you don't have time to watch all of this excellent presentation on:

+ how HDL can become "bad."...

+how to properly test for it...

......**and the importance of "knowing" the IMPACT of medications that "raise good HDL"

then at least watch from 43:04 forward in the Q&A session**

http://www.youtube.com/watch?v=H_rPFF5X-pc

(Title: When Good Cholesterol Goes Bad )

In the clinical investigation between physician and client is there some danger in prescribing these medications without doing more advanced laboratory investigation of the existing nature of the the patient's HDL performance ( not just presence).
According to this researcher even APoA 1/HDL comparisons are not good enough.
Therefore the first step is to ensure the best laboratory assessment tool is in place first.